We also tested a patient-derived xenograft model of EGFR mutant lung cancer (MGH134-1) and again observed the greatest antitumor effects from the combination treatment of osimertinib with an anti-CD47 antibody (Figure 5B and Supplemental Figure 15). Here, CD47 is linked to lung carcinoma.